✦ LIBER ✦

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

✍ Scribed by Etienne, Gabriel; Lobo, Clarisse; Pasquini, Ricardo; Clark, Richard E.; Hochhaus, Andreas; Hughes, Timothy P.; Saglio, Giuseppe; Kim, Dong-Wook; Issaragrisil, Surapol; le Coutre, Philipp

Book ID: 111694593
Publisher: Massachusetts Medical Society
Year: 2010
Tongue: English
Weight: 394 KB
Volume: 362
Category: Article
ISSN: 0096-6762
DOI: 10.1056/nejmoa0912614

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dasatinib versus Imatinib in Newly Diagn

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

✍ Kantarjian, Hagop; Shah, Neil P.; Hochhaus, Andreas; Cortes, Jorge; Shah, Sandip 📂 Article 📅 2010 🏛 Massachusetts Medical Society 🌐 English ⚖ 260 KB

Imatinib for newly diagnosed chronic-pha

Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan

✍ Tadashi Nagai; Jin Takeuchi; Nobuaki Dobashi; Yuzuru Kanakura; Shuichi Taniguchi 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 284 KB

Nilotinib vs imatinib in patients with n

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

✍ Larson, R A; Hochhaus, A; Hughes, T P; Clark, R E; Etienne, G; Kim, D-W; Flinn, 📂 Article 📅 2012 🏛 Nature Publishing Group 🌐 English ⚖ 351 KB

Nilotinib, imatinib, and telomere homeos

Nilotinib, imatinib, and telomere homeostasis disruption in chronic myeloid leukemia : Reply to nilotinib versus imatinib: Molecular mechanism(s) of its better efficacy

✍ Franck E. Nicolini; Paul W. Manley; Tim H. Brümmendorf 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 436 KB

High-dose imatinib for newly diagnosed c

High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients—Systematic review and meta-analysis

✍ Anat Gafter-Gvili; Avi Leader; Ronit Gurion; Liat Vidal; Ron Ram; Adi Shacham-Ab 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 319 KB 👁 1 views

## Abstract Imatinib at a dose of 400 mg daily is considered frontline treatment in chronic phase chronic myeloid leukemia (CP‐CML). We conducted a systematic review and meta‐analysis of randomized controlled trials comparing frontline treatment with imatinib 400 mg daily versus higher doses (≥600

Cost-effectiveness of imatinib versus in

Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

✍ Shelby D. Reed; Kevin J. Anstrom; Jennifer A. Ludmer; G. Alastair Glendenning; K 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 1 views

## Abstract ## BACKGROUND Despite a lack of long‐term data, imatinib has become standard therapy for patients with newly diagnosed chronic‐phase chronic myeloid leukemia (CML) who are not candidates for allogeneic stem cell transplantation. In the current study, the authors estimated the increment